Justin Klaff

Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE…

˜The œLancet. Gastroenterology & hepatology · 2023 · 54 citations

Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis

Alimentary Pharmacology & Therapeutics · 2024 · 29 citations